BioRegenx Announces Board and Executive Changes
Ticker: BRGX · Form: 8-K · Filed: Oct 11, 2024 · CIK: 1593184
| Field | Detail |
|---|---|
| Company | Bioregenx, INC. (BRGX) |
| Form Type | 8-K |
| Filed Date | Oct 11, 2024 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 2 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: management-change, board-composition, executive-compensation
TL;DR
BioRegenx swapped some execs and board members, and tweaked pay. Keep an eye on this.
AI Summary
BioRegenx, Inc. announced on October 7, 2024, a change in its board of directors and executive compensation arrangements. Specifically, the company reported the departure of certain officers and directors, the election of new directors, and adjustments to compensatory arrangements for its key executives. The filing details these changes as part of its routine reporting requirements.
Why It Matters
Changes in a company's board and executive compensation can signal shifts in strategy, governance, or financial health, impacting investor confidence and future performance.
Risk Assessment
Risk Level: medium — Changes in executive and board composition can indicate internal shifts that may affect the company's future direction and stability.
Key Players & Entities
- BIOREGENX, INC. (company) — Registrant
- October 7, 2024 (date) — Date of earliest event reported
- Nevada (jurisdiction) — State of incorporation
- 7407 Ziegler Road (address) — Principal executive offices
- Chattanooga, Tennessee 37421 (address) — Principal executive offices
FAQ
What specific roles have been affected by the departure of officers or directors?
The filing indicates a departure of certain officers and directors but does not specify the exact roles affected in this section.
When was the earliest event reported in this 8-K filing?
The earliest event reported was on October 7, 2024.
What is the state of incorporation for BioRegenx, Inc.?
BioRegenx, Inc. is incorporated in Nevada.
What are the principal executive offices of BioRegenx, Inc.?
The principal executive offices are located at 7407 Ziegler Road, Chattanooga, Tennessee 37421.
What items are being reported under Section 13 or 15(d) of the Securities Exchange Act of 1934?
The filing reports on the departure of directors or certain officers, election of directors, appointment of certain officers, and compensatory arrangements of certain officers.
Filing Stats: 483 words · 2 min read · ~2 pages · Grade level 11.6 · Accepted 2024-10-11 17:15:10
Filing Documents
- bioregenx_8k.htm (8-K) — 20KB
- 0001683168-24-007111.txt ( ) — 183KB
- fdit-20241007.xsd (EX-101.SCH) — 3KB
- fdit-20241007_lab.xml (EX-101.LAB) — 33KB
- fdit-20241007_pre.xml (EX-101.PRE) — 24KB
- bioregenx_8k_htm.xml (XML) — 3KB
02 Departure of Directors or Certain Officers; Election of
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. (d) On October 7, 2024, BioRegenx, Inc., a Nevada corporation ("BioRegenx") appointed Richard Janney to serve as a member of its board of directors until his successor is elected and qualified, or until he resigns or is removed. There is no arrangement or understanding between Mr. Janney and any other person pursuant to which he was selected as a director. Mr. Janney is not currently a participate in any material plan, contract or arrangement with BioRegenx and has not received any grant or award pursuant to any such plan, contract or arrangement. On October 7, 2024, the board formed an audit committee. Mr. Janney and Suzanne Bird (existing director of BioRegenx) were named to the audit committee. Since the beginning fiscal 2023, there have not been any transactions, and there are not any currently proposed transactions, in which BioRegenx was, or is to be, a participant and in which Mr. Janney had, or will have, a direct or indirect material interest.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. BioRegenx, Inc. (Registrant) Date: October 11, 2024 By: /s/ William Resides Name: William Resides Title: Chief Executive Officer 2